New Executive Leadership to Drive Bitcoin Mining OperationsSino-Global Announces New Executive Leadership to Drive Bitcoin Mining Operations Expansion
announced today that the newly appointed Chief Operating Officer Mr. Lei Nie and Chief Technology Officer Mr. Xintang You will spearhead the Company's effort to enter Bitcoin mining.
As Sino-Global evaluates its strategy for 2021 and beyond, the planned Bitcoin mining expansion follows a series of steps in preparation.
The plan utilizes leadership team members who specialize in information technology, Blockchain, cryptocurrency mining operations and more. Given the Company's plan to enhance the traditional logistics service platform through leveraging innovative technologies, the Company is excited to explore opportunities created by current market conditions and enter the cryptocurrency sector.
finance.yahoo.com
Stockstowatch
3 potential stocks to expand your portfolioThinking about which financial instrument to add to your portfolio is always a challenging task, especially in a market where almost everything is overbought. You may already own these three stocks, but if you don't they have good technicals and fundamentals to get in or to add up. Starting first with the Ferrari. At first, sounds like an exotic stock, but the race-car manufacturer is still on track. And it's not because of the newly born millionaires from the latest rise in the price of Bitcoin ...
Let's take a look at what's under the "hood" of Ferrari. Technically we have a well-formed uptrend and Yesterday that trend was tested at the earnings which were good. Volumes activity was big since the bottom formed after the first lockdown. The candle formation ended with a pinbar . MACD and RSI are still lagging, but the trend holds. Fundamentally the financial look of the company is stable in revenue and EPS aspect. Also, the racing car manufacturer is decided to take on the electric cars market, as well as delivering three new models.
Next is Nio. Already a familiar company and attracting more and more investors. Earnings are on the 9th of March. Revenues and EPS are shaky, but investors are betting on the long-term success of the company. Ford terminated their contract to manufacture electric cars in China, but Nio managed to cement their position in the Asian country. MACD here is lagging, but RSI is moving above 50 and the trend is intact. The price is currently forming a bullish flag on the daily chart and if it is triggered we may head towards the $70 range.
Last, but not least - Raytheon . Technicals are looking better here as RSI is moving from oversold territory and above 50. MACD has a crossing and the histogram is starting to move into positive territory. The uptrend is intact. Earnings passed, although they are a bit disappointing, financials are looking stable for the company. The company recently won a $290 million contract with the U.S. Navy. That will attract more revenue for the company and will keep it busy in the long-term.
Purchase Order for HybridTech Armor© Panels for Aircraft CarrierCPS Technologies Corporation receives Purchase Order for HybridTech Armor© Panels for Aircraft Carrier
CPSH today announced receipt of a purchase order for HybridTech Armor© Panels to be installed as the strike face of advanced ballistic shields to support U.S. Navy CVN class ships.
The purchase order covers panels to equip all crew-served weapons stations on one aircraft carrier.
We have received a $28.7 million IDIQ contract from the Navy to address the aircraft carrier fleet, with an initial delivery order for the first aircraft carrier.”
finance.yahoo.com
Payoneer to Become Publicly Traded Company Through FTACPayoneer to Become Publicly Traded Company Through Combination With FTAC Olympus Acquisition Corporation
Payoneer processed more than $44 billion in volume in over 7,000 trade corridors in 2020
Transaction assigns Payoneer $3.3 billion pro-forma implied enterprise value upon , representing a 7.6x multiple of 2021 expected revenue of $432 million. The cash component of the purchase price to be paid to the equity holders of Payoneer is expected to be funded by FTOC's cash in trust (minus any redemptions by FTOC's existing public stockholders).
Includes commitments for $300 million PIPE from investor group including existing investor Wellington Management, as well as Dragoneer Investment Group, Fidelity Management & Research Company LLC, Franklin Templeton, certain funds managed by Millennium Management, funds and accounts advised by T. Rowe Price Associates, Inc., and Winslow Capital Management, LLC
Following the Reorganization, the Company is expected to have up to $563 million in cash, offering significant capital flexibility for continued organic and inorganic growth.
Existing Payoneer equity holders have the potential to receive an earnout of additional shares of common stock if certain stock price targets are met as set forth in the reorganization agreement, and they will remain the largest investors by rolling over significant equity into the Company.
The transaction is expected to close during the first half of 2021.
finance.yahoo.com
$TRIP $TRUFF A nice Cup and Handle forming as we make it towards the end of the week. Perfect timing with the upcoming news release.
Red Light Holland has already made it known that they want to be the forefront in Psychedelics. To date, i've noticed a strong campaign regarding branding and increasing company exposure/ psychedelic acceptance. I do like that Bruce Linton is also the Chairman of Advisory Board
To note: Red Light Holland making an APP to share personal stories of Microdosing?.. Along with a Job-Contest coming up for Feb 8th?..
I do not see this staying at these levels much longer. GLTA
- Pocketfeeder
$MRS $MSNVF Breakout ImminentLooks like MRS is Mission Ready. New floor at ~ 0.30, so it may be a good time to get in. Although it's forming a nice Wedge and looking for a breakout.. here's a couple things to note:
1. Several government contracts
2. Revenues for first quarter in 2021 likely ~$500M
3. Covid-19 cases/deaths all time high, increased demand for PPE (has become an addition to PPE supply)
4. PPE supplier for LYFT
5. ***Most Importantly, MRS uplist in the near future
PT- >$1.00
GLTA!
- Pocketfeeder
Analysis request: CCIV Long above 32.02Id like to see support continue above $28.00 on top of the current support zone, and above the orange trend.
The RSI is still cooling down a little and i wouldnt be suprised if we retrace further to the likes of 25.30 if we dont hold 28.
Id expect trading to continue above the current trend line (Red), but if we fall below, id be watching for 22.69 for support
Bearish below 25.30, bullish above 32.02, id stop out on a short term position under 25, or 22.69
It may take another day of red before buyers have an edge, and we resume to the upside.
CLA Long to 15.29, Golden mean reversalKeeping an eye on CLA for a reversal above the yellow 1W trend, and support above our weekly resistance at 13.50
Last months open at 13.85 is currently our resistance, and again around 14.20
If you fall under either the weekly resistance or the green support line, id be bearish until we recovered.
Depending on the trade, id consider 12.53 a good stop loss, leaving it just under historical support.
If you wanted to tighten it up, i think 12.99 should be a safe on the 4HR as well for a short term confirmation.
30m chart looks like a nice bull flag consolidation , the 200 MA is under the 50 MA, bullish confluence on the RSI.
if we can hold up these key levels, id expect to see a reversal in the near future to 15.29
$VCNX PT 8 and higher (@snow6)Vaccinex, Inc., a clinical-stage biotechnology company, discovers and develops bio therapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab that is in clinical development stage for the treatment of non-small cell lung cancer (NSCLC), Huntington's disease, osteosarcoma, melanoma, and Alzheimer's disease. The company is also developing VX5, a human antibody to CXCL13 that is in preclinical development for the treatment of MS and potentially for other autoimmune disorders; and VX25, a bi-specific natural killer T (NKT) cell stimulator, for the therapeutic application of NKT cell stimulation for cancer immunotherapy. It has a clinical trial collaboration and supply agreement with Merck KGaA to test pepinemab in combination with avelumab checkpoint inhibitor in NSCLC patients. Vaccinex, Inc. was founded in 2001 and is headquartered in Rochester, New York.
Broker a dealReversal setup to the upside
Reward/Risk: 3.1/1
Entry: 53.59 or at a lower price
Stop: 50.00
Target: 63.00
Be your own masterRange Trade
Reward/Risk: 2/1
Entry: 332.60 or at a lower price
Stop: 310.00
Target: 375.00
Any Economic recovery should be a tailwind for the stock
taking chance play with AMDRange Trade
Reward/Risk: 2.44/1
Entry: 89.00 or at a lower price
Stop: 83.00
Target: 100.00
100% Survival Achieved in Osteosarcoma Lung MetastasesMoleculin Announces 100% Survival Achieved in Osteosarcoma Lung Metastases Animal Model
a preclinical study in animals demonstrated a potentially significant therapeutic benefit of Annamycin against metastatic osteosarcoma.
Computerized tomography (CT) scans demonstrated that animals treated with Annamycin exhibited significant suppression of tumor growth and not a single death was observed in the treated animals, whereas significant tumor burden contributed to the rapid death of 90% of untreated animals. While the study continues, as of day 130, the survival rate for animals treated with Annamycin was 100%, compared with only 10% for untreated animals.
Annamycin is a "next generation" anthracycline that has recently been shown in animal models to accumulate in the lungs at up to 34 times the level of doxorubicin, which may account for the 100% survival rate attained in this most recent osteosarcoma lung metastases study.
Moleculin recently announced that the FDA has allowed the Company's request for investigational new drug (IND) status in order to study Annamycin for the treatment of soft tissue sarcoma metastasized to the lungs. In addition, the FDA granted Orphan Drug Designation for Annamycin for the treatment of soft tissue sarcomas.
"We expect that one, and potentially two, clinical trials in sarcoma lung metastases should be up and running this year."
finance.yahoo.com
Breakout out setup #stocksBreakout setup to the upside
Reward/Risk: 2/1
Entry: 87.81 or at a lower price
Stop: 84.00
Target: 94.00
$MINE Weekly ChartBull flag break out and the rise of cup is in the making. The top of the cup on the weekly chart is $1.20. For those long term holders you will be very happy for the retrace.
Space launch company Astra to go public via merger with SPAC HOLastra-to-become-the-first-publicly-traded-space-launch-company-on-nasdaq-via-merger-with-holicity
BlackRock-managed funds and accounts lead investment in Astra to launch a new generation of space services to improve life on Earth.
The transaction reflects an implied pro-forma enterprise value for Astra of approximately $2.1 billion. Upon closing, the transaction is expected to provide up to $500 million in cash proceeds, including up to $300 million of cash held in the trust account of Holicity and an upsized $200 million PIPE led by funds and accounts managed by BlackRock.
In December 2020, Astra joined a small, elite group of companies that have made it to space. With over 50 launches in manifest across more than 10 private and public customers, including NASA and DOD, Astra has booked over $150 million of contracted launch revenue. Astra will begin delivering customer payloads this summer and begin monthly launches by the end of this year.
The proposed transaction, which is expected to be completed in the second quarter of 2021.
astra.com
Book it #stocksRange retest setup to the upside
Reward/Risk: 2/1
Entry: 2067.00 or at a lower price
Stop: 1800.00
Target: 2500
Reversal Play #stocksEntry: 112.10 or a lower price
Stop: 105.00
Target: 132.00
Good risk/reward reversal setup to the upside after trendline break looking for price to head back toward the range (rectangle)
GSM Announces potential financing arrangements being discussedFerroglobe Announces Discussions with Ad Hoc Group of Noteholders and Key Financial Partners
Ferroglobe PLC (the “Company”) entered into confidentiality agreements (the “Confidentiality Agreements”) with certain holders (the “Ad Hoc Group of Noteholders”) of the 9.375% Senior Notes due 2022 (the “Notes”) issued by the Company and Globe Specialty Metals, Inc., to facilitate discussions addressing the maturity of the Notes and the introduction of further capital to the Company.
The key highlights of the potential financing arrangements being discussed between the AHG and the Company are as follows:
A major recapitalization of the business with $100 million of additional liquidity which guarantees sufficient funding to implement the Company’s strategic plan
$60 million of new super senior notes provided by existing Noteholders
$40 million of new equity funding
Significant extension of the Company’s debt maturity profile as a result of a par exchange of the Notes with new senior secured notes with a 5 year tenor
Equity allocation of 3.75% to all supporting holders of the Notes facilitating greater alignment of all stakeholders with management on strategy and long-term value creation
The Company is negotiating with key stakeholders, including its largest shareholder Grupo Villar Mir, S.A.U., the injection of equity that is required to implement the proposed plan and is aiming to enter into a binding agreement with the Ad Hoc Group of Noteholders and equity providers reflecting the outcome of the discussions as soon as possible (although no assurance can be made that the discussions will be successful or that the new funding will be implemented).
The contemplated financings offer Ferroglobe a stronger balance sheet and incremental capital which, in turn, provide a sound foundation for transforming the Company.
the Company has been diligently evaluating various refinancing options to address its senior notes, alongside raising incremental capital.
Collectively we are working towards a comprehensive financing that eliminates near-term refinancing risks, providing greater operational flexibility, and secures cash for the implementation of our plan.
finance.yahoo.com
Reddit Traders Are Taking Aim at Silver stock $LODE$LODE Would also be one of my top picks if we are entering a Silver Bubble over the next month.
You can clearly see that it's a reverse split and has the lowest float for a silver miner that I could find.
This came after a surge in retail trading pushed the price of silver to an eight-year high. As the war between Reddit board traders and hedge funds continues, it seems to me that a “silver squeeze” could be imminent. Popular subreddit r/WallStreetBets (WSB) could be hinting to bank on silver stocks, which sent prices of the semi-precious metal sharply higher late last week. In detail, one Reddit poster mentioned that the silver bullion market could also be one of the most manipulated on Earth. The user also encouraged many other retail investors to trigger a short squeeze in silver paper shorts.
Now to be fair, we know that there is a strong demand for the uses of silver. From solar panels to electric cars and electronics, silver has an enormous appeal as a precious metal and industrial asset. Could silver stocks be the next target for Reddit day traders and their crowdsourcing power? If so, we could be seeing another rally that GameStop (NYSE: GME) has enjoyed so far this year.
Whether or not WSB’s obsession with silver is short-lived remains to be seen, but there’s no question that $LODE stock and other top silver stocks are heating up right now. With all that being said, do you have a list of top silver stocks to buy amid silver’s rapid rise?
www.nasdaq.com
Reversal SetupAfter 2 down months SWK might be heading back toward highs. Also showing positive rate of change divergence
Long here with a stop on a close below 167.00 with a target at 197.00
Sunlight Financial LLC to List on NYSE Through Merger With SPRQSunlight Financial LLC, a Premier Residential Solar Financing Platform, to List on NYSE Through Merger With Apollo-Affiliated Spartan Acquisition Corp. II
Sunlight and Apollo-Affiliated Spartan Acquisition Corp. II (NYSE: SPRQ) Enter Into Business Combination Agreement
Institutional Investors Led By Chamath Palihapitiya, Coatue, Funds and Accounts Managed by BlackRock, Franklin Templeton and Neuberger Berman Commit to Invest $250 Million at Closing in Common Stock PIPE at $10.00 per Share
Pro Forma Implied Equity Value of the Combined Company is Approximately $1.3 Billion
Sunlight has arranged financing for more than an estimated 100,000 residential solar systems, which will produce over 500 megawatts of solar-generated electricity and avoid more than 10 million metric tons of carbon dioxide emissions.
Leading POS platform through which over $3.5 billion of loans have been originated in the rapidly growing residential solar market
Upon the closing of the transaction, existing Sunlight equityholders are expected to own approximately 50% of the combined company, Spartan stockholders are expected to own approximately 26%, and PIPE participants are expected to own approximately 19%.
The transaction is expected to close in the second quarter of 2021.
finance.yahoo.com
